Heart failure (HF) is a highly prevalent disease with considerable morbidity and mortality. It is estimated that approximately 50 million people are afflicted with this disease worldwide. The disease burden of HF represents one of the most serious health concerns facing society today (1, 2). Prognosis of HF remains unsatisfactory, and multiple comorbidities with HF impede therapeutic options. Among patients with HF, type 2 diabetes mellitus (T2DM) is a fairly common comorbidity that is present in 20–40% of all patients (3).
